Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection

• Published in: Antiviral chemistry & chemotherapy Vol. 26; p. 2040206618756430
• Main Author: Dousson, Cyril B
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-01-2018; Sage Publications Ltd
• Subjects: Clinical trials; Drug discovery; Drug interaction; Hepatitis; Hepatitis C; Interferon; Liver; Prodrugs; SI: Advances in Antiviral Nucleoside Analogs and Their Prodrugs; nucleoside analogs; nucleotide analogs; Hepatitis C virus; prodrugs; NS5B
• ISSN: 2040-2066; 0956-3202; 2040-2066
• DOI: 10.1177/2040206618756430

This review describes the current state of discovery of past most important nucleoside and nucleotide prodrugs in the treatment of hepatitis C virus infection as well as future potential drugs currently in discovery or clinical evaluation. I highlight first generation landmark prodrug compounds which have been the foundations of incremental improvements toward the discovery and approval milestone of Sofosbuvir. Sofosbuvir is the first nucleotide prodrug marketed for hepatitis C virus treatment and the backbone of current combination therapies. Since this approval, new nucleotide prodrugs using the same design of Sofosbuvir McGuigan prodrug have emerged, some of them progressing through advanced clinical trials and may become available as new incremental alternative hepatitis C virus treatments in the future. Although since Sofosbuvir success, only minimal design efforts have been invested in finding better liver targeted prodrugs, a few novel prodrugs are being studied and their different modes of activation may prove beneficial over the heart/liver targeting ratio to reduce potential drug–drug interaction in combination therapies and yield safer treatment to patients. Prodrugs have long been avoided as much as possible in the past by development teams due to their metabolism and kinetic characterization complexity, but with their current success in hepatitis C virus treatment, and the knowledge gained in this endeavor, should become a first choice in future tissue targeting drug discovery programs beyond the particular case of nucleos(t)ide analogs.